Simparica Trio Now Fights Lyme Disease
The chewable parasiticide Simparica Trio has earned an additional label indication for the prevention of Borrelia burgdorferi infections, the cause of canine Lyme disease.
The U.S. Food and Drug Administration previously approved Simparica Trio (sarolaner/moxidectin/pyrantel) to protect dogs against heartworm disease, ticks, fleas, roundworms and hookworms. The new indication applies to the black-legged tick, also known as the deer tick, which the preventive is formulated to kill.
“This new efficacy claim provides a new tool to veterinary teams, who understand that healthy pets mean happy people and who work every day to provide the best care for our dogs,” said Jen Sheehy, DVM, the medical lead for parasitology at Zoetis Inc., the manufacturer of Simparica Trio.
Given monthly, the preventive is approved for dogs 8 weeks or older and at least 2.8 pounds.
According to Zoetis, 1 in 20 U.S. dogs tested positive for Lyme infection in 2020.
“Once dogs are infected with Borrelia burgdorferi, the bacteria’s unique mode of motility allows it to rapidly disseminate throughout the body. This can make the infection difficult to treat,” said Richard T. Marconi, Ph.D., a microbiology and immunology professor at Virginia Commonwealth University, speaking on behalf of Zoetis. “The most important thing we can do is to prevent infection in the first place using a comprehensive strategy that includes the use of an effective tick preventative product and vaccination.”
Dechra Acquires Isoflurane and Sevoflurane
Dechra Veterinary Products announced plans to launch two veterinary-branded inhalant anesthetics — Isoflurane and Sevoflurane — in the first quarter of 2022.
The drugs were acquired from Halocarbon Life Sciences. Details of the transaction were not released.
“These products are utilized daily in veterinary hospitals and complement our current sedative and anesthetic product range,” said Mike Eldred, president of Dechra North America.
Among Dechra’s other companion animal products are Vetoryl Capsules, for the treatment of pituitary-dependent hyperadrenocorticism in dogs, and Mirataz, for the management of weight loss in cats.
Multi Radiance Medical Sponsors CE Courses
Laser therapy device maker Multi Radiance Medical has partnered with Northeast Seminars and the University of Tennessee College of Veterinary Medicine to sponsor four certification programs.
They include certified canine rehabilitation practitioner (CCRP), certified equine rehabilitation practitioner (CERP), certified canine manual therapist (CCMT) and certified small animal myofascial practitioner (CSMP).
“In each course, participants will learn about (Multi Radiance) laser therapy in online lectures and then apply their knowledge in hands-on lab sessions,” the company reported. “This hybrid online/in-person program provides a well-rounded education on the most current and relevant modalities and techniques necessary for successful outcomes.”
Details are available at utvetce.com.
Did you know a subscription to Today’s Veterinary Business is free to qualified veterinary professionals? All you have to do is sign up here (and renew each year). You also can sign up to receive the Today’s Veterinary Business weekly e-newsletter.